The mitochondrial respiratory chain (MRC) is composed of four multienzymatic complexes embedded in the mitochondrial inner membrane (MIM) of eukaryotes and of two electron carriers, cytochrome c (cyt c) and Coenzyme Q 10 (CoQ 10 ) or ubiquinone.
CoQ is a lipophilic molecule present in all cell membranes; its structure consists of a benzoquinone ring bound to a hydrophobic polyisoprenic tail of variable length, depending on the different species (ten units in humans, nine in mice, six in yeast) 1 . Beyond its fundamental role as electron carrier, CoQ has many other functions, including its involvement in pyrimidine biosynthesis, cell growth and differentiation, counteraction of apoptosis, mitophagy, functional modification of mitochondrial uncoupling proteins 2, 3 and regulation of sulfide metabolism 4, 5 ; moreover, in its reduced form it is the only lipid-soluble antioxidant synthesized endogenously 6 . CoQ biosynthesis requires a series of proteins encoded by COQ genes and has been extensively studied in bacteria and yeast 7, 8 . Currently, the complete metabolic biosynthetic pathway remains to be elucidated 9, 10 and in humans thirteen genes required for CoQ 10 biosynthesis have been identified so far 11 . Defects of ubiquinone biosynthesis cause CoQ 10 deficiencies, a group of clinically and genetically heterogeneous conditions [12] [13] [14] . Mutations in ten COQ genes have been associated with primary CoQ 10 deficiencies 11, 15 . Depending on the localization and extent of the defect, the clinical symptoms vary greatly: the brain, the cerebellum, the muscle and/or the kidney may be involved, usually resulting in complex disease patterns 16 . Fibroblasts and muscle of affected individuals present a decrease of combined activities of Complex I + III (CI + III) and II + III (CII + III) 17 (two CoQ 10 -dependent reactions). Patients with primary CoQ 10 deficiency respond well to ubiquinone oral administration [18] [19] [20] , but this approach is not completely effective, in part also because of the poor bioavailability of CoQ 10 related to its extreme hydrophobicity 21, 22 . Consequently, CoQ 10 supplementation requires high doses (up to 30-50 mg/kg/day) 14 www.nature.com/scientificreports www.nature.com/scientificreports/ analogs [23] [24] [25] [26] [27] . Ubiquinol-10, the reduced form of CoQ 10 , was found to have the same efficiency at a lower dosage than its oxidized form in a patient with CoQ 10 deficiency, due to its better bioavailability 28 . It was also shown to be more effective in ameliorating the phenotype of a CoQ-deficient mouse model with mitochondrial encephalopathy 29 . However, experience in patients with primary forms is currently limited. The CoQ 10 precursor 4-hydroxybenzoic acid (4-HB) and its analogs 2,4-dihydroxybenzoic acid (2,4-diHB), 3,4-diHB and vanillic acid exhibit beneficial effects on CoQ 10 deficient cells in vitro, and 2,4-diHB rescued the mutant phenotypes of two different mice models of ubiquinone deficiency 15, [30] [31] [32] . Vitamin K2 (menaquinone-4, MK-4) is an isoprenoid quinone like CoQ 10 , containing a naphtoquinone ring and shorter isoprenoid side chain. Thus, vitamin K2 is less lipophilic than CoQ 10 and it acts as electron carrier in some bacterial species 33 . A previous study suggested that vitamin K2, similarly to CoQ 10 , contributes to electron transport in the MRC of D. melanogaster 34 and hence it could represent a promising drug to treat mitochondrial diseases, and specifically defects in ubiquinone biosynthesis.
In this work we tested whether vitamin K2 and Coenzyme Q 4 (CoQ 4 , an analog of CoQ 10 with a shorter isoprenoid side chain) could substitute CoQ function in human and yeast cells with CoQ deficiency.
Results
Vitamin K2 is incorporated into human mitochondria. In a first set of experiments, we checked whether vitamin K2 enters the cells and if it reaches mitochondria when it is added to the culture media as an aqueous solution. Cells were supplemented with vitamin K2 (5 μM) for 1 week and, after lipid extraction, vitamin K2 levels were determined by reverse phase HPLC with electrochemical detection (ECD). Untreated cells had no detectable vitamin K2, while in vitamin K2-treated cells the chromatogram displayed a clear peak at 4.7 min identical to the standard (Fig. 1a) .
We then analyzed the subcellular distribution of vitamin K2. A cellular fractionation of MK-4-treated cells was carried out by differential centrifugation, resulting in three different fractions: F1 constituted by nuclei and unbroken cells, an enriched-mitochondrial fraction F2, and F3 that included cytosol, endoplasmic reticulum, Golgi apparatus, peroxisomes, lysosomes and the other light membranes. These fractions were analyzed by western blot using antibodies against Complex IV subunit 4 (COX4) as mitochondrial marker, lamin A/C as nuclear marker, and APAF1 as cytosolic marker (Fig. 1b) . Lipid extracts were prepared from each fraction, and Vitamin K2 does not restore electron flow in the respiratory chain of cells with CoQ10 deficiency. We evaluated the effects of vitamin K2 supplementation on CII + III combined activities in CoQ 10 deficient fibroblasts with mutations in COQ2 (P1) 36 . P1 fibroblasts were incubated with 5 μM CoQ 10 or vitamin K2 for one week. CII + III activity was determined spectrophotometrically by following the reduction of 50 μM cyt c at 550 nm. As shown in Fig. 2a , untreated fibroblasts had 20% residual CII + III activity relative to controls (these cells harbor a hypomorphic allele that allows a residual production of CoQ 10 37 ). Only CoQ 10 -treated cells showed a normalization of mitochondrial CII + III activity, whereas vitamin K2 had no effect. As a further control we employed the more soluble decyl-ubiquinone (DUB) that could largely rescue the CII + III enzymatic defect when added to the cuvette.
To exclude a mutation-specific effect, we repeated the experiment using fibroblasts (P2) with a different genetic defect in COQ2 38 , and similar results were obtained. In this case we also tested the effect of CoQ 4 , a short chain quinone that is less lipophilic than CoQ 10 (the isoprene chain is similar to that of vitamin K2). Supplementation with 5 μM CoQ 4 for 1 week was able to restore normal CII + III activity (Fig. 2b) .
We then employed a different system to induce CoQ 10 deficiency. HEK293 cells were treated with 4 mM 4-nitrobenzoate (4-NB), a selective inhibitor of CoQ 10 biosynthesis 39 , for 7 days. This treatment decreased CII + III activity by ~50%, and the addition of CoQ 10 could rescue MRC functionality, whereas we did not observe any effect after vitamin K2 supplementation (Fig. 2c) . −/− cells displayed a strong decrease of CII + III activity compared to controls (Fig. 2d) . Only cells supplemented with CoQ 10 or CoQ 4 displayed a rescue of the biochemical defect.
Finally, we also analyzed the ATP content in COQ4 −/− cells treated with 5 μM CoQ 10 , vitamin K2 or CoQ 4 for one week. (Fig. 2e) . While CoQ 10 and CoQ 4 were largely able to rescue the bioenergetic defect, increasing ATP to levels comparable to control cells, vitamin K2 was not effective. To further support these results, we repeated the same experiment using patient's fibroblasts with CoQ 10 deficiency (P1) and obtained similar results (see Supplementary Fig. S1 ).
To test whether treatment with CoQ 4 might affect CoQ 10 content, we also measured CoQ 10 levels in HEK293 cells treated for 7 days with 5 μM CoQ 10 , vitamin K2 or CoQ 4 . As expected, CoQ 10 content was increased in cells treated with CoQ 10, while it was essentially unchanged in cells treated with either vitamin K2 or CoQ 4 , suggesting that the two compounds are not affecting CoQ 10 biosynthesis (see Supplementary Fig. S2 ).
Vitamin K2 does not restore respiratory growth of yeast COQ mutants. In a final set of experiments, we employed the S. cerevisiae ΔCOQ6 strain as additional model to test the effect of exogenous vitamin K2 on lower eukaryotes. This strain is unable to grow on non-fermentable carbon sources (ethanol and glycerol) if not supplemented with coenzyme Q 6 (CoQ 6 ) 41 . The ΔCOQ6 strain was transformed with the WT yCOQ6 as control or its mutant versions: the catalytically inactive but structurally stable F455X allele 42 and the G386A_ N388D double mutant 43 . Yeast growth was analyzed on a medium containing glycerol as a non-fermentable carbon source (YPG), with or without 50 μM vitamin K2. Vitamin K2 was not able to rescue the defective growth in the ΔCOQ6 strain (see Supplementary Fig. S3 ).
To exclude that the lack of rescue by exogenous vitamin K2 could be due to the inability of the compound to reach yeast MIM, we treated wild-type yeast with 50 μM vitamin K2 for 2 days and quantified vitamin K2 content by HPLC separation and ECD, after mitochondria purification and lipid extraction. As in human cells, we found that yeast mitochondria also uptake vitamin K2 significantly (see Supplementary Fig. S3 ).
Overall, these findings indicate that vitamin K2 is not active as electron carrier in the MRC of S. cerevisiae, or in that of human cells.
Vitamin K2 is not an efficient substrate for complex II in human cells in vitro.
Finally, we repeated the experiment performed by Vos and coworkers to test the electron acceptor capability of vitamin K2 compared to CoQ 10 . However, we also included as further controls DUB, a good electron acceptor for Complex II (CII) in vitro, and CoQ 4 . We measured CII activity by following the reduction of the 2,6-dichlorophenolindophenol (DCPIP) at 600 nm in mitochondrial-enriched fractions from HEK293 cells. As seen in Fig. 2f , neither CoQ 10 nor vitamin K2 are good substrates for this reaction, since the activity measured with these compounds is almost two orders of magnitude inferior to that measured with DUB, at comparable concentrations.
Discussion
Primary CoQ 10 deficiency is one of the few treatable mitochondrial disorders, since oral supplementation with CoQ 10 improves the symptoms of patients with different COQ genes defects 44 . Moreover, CoQ 10 has been widely used for the treatment of patients with mitochondrial disorders because they frequently display secondary deficiency 45 . However, CoQ 10 bioavailability and mitochondrial targeting are low due to its high hydrophobicity. Therefore, in the last years many efforts have been made to identify more water-soluble analogs of CoQ 10. The use of certain oxidized or reduced CoQ 10 dosages and formulations is able to increase ubiquinone levels in all human tissues after oral administration 46 . Also the use of 4-HB analogs is a promising strategy to bypass defective steps in the CoQ 10 biosynthetic pathway 47 . Vos and coauthors have proposed that vitamin K2 can function as an electron carrier in the MRC of a multicellular eukaryote, D. melanogaster 34 . The structure of vitamin K2 is similar to CoQ 10 , but it has a shorter hydrophobic carbon chain tail with four prenyl units that confer higher hydrophilicity. Because of the better bioavailability of vitamin K2, these findings opened the possibility that it could substitute CoQ 10 in deficient patients.
To test this hypothesis, we have employed cells in which CoQ 10 biosynthesis was disrupted or inhibited either by genetic or pharmacological means. Our results do not support the notion that vitamin K2 can act as an electron carrier in eukaryotic cells. In fact, even though it can easily reach mitochondria, vitamin K2 could not restore either electron flow or ATP biosynthesis in CoQ 10 -deficient cells.
One of the experiments performed by Vos and coworkers to support their claims showed that CoQ 10 and vitamin K2 act as electron acceptors from complex II in vitro 34 . However, we now show that neither compound is a good in vitro substrate for Complex II compared to what is considered a good one, DUB 48 . In fact, the ability of vitamin K2 to accept electrons is about two orders of magnitude lower than that of DUB, and the situation for CoQ 10 is only slightly better. Therefore, it is impossible to draw any conclusions from this experiment.
In agreement with our results, vitamin K2 failed to rescue mouse embryonic fibroblasts (MEFs) that are deficient for MCLK1 (the orthologue of human COQ7), where it could not restore the respiratory defect caused by CoQ 10 deficiency 24 .
One of the limitations of our study is that we could not use D. melanogaster cells to exclude that the different results obtained in that model could be due to a species-specific effect. Nevertheless, our data clearly show that the role of vitamin K2 as an electron carrier (if confirmed) is probably restricted to Drosophila, and is not a general phenomenon in eukaryotic cells.
Finally 49 . Our data highlight that the effectiveness of electron transport in the MRC critically depends on the length of the isoprenoid chain, suggesting that two additional isoprenoid groups are sufficient to ensure the interaction with respiratory complexes binding sites. However, the mechanisms underlying these differences remain to be elucidated.
Although short chain quinones are toxic, this is particularly true for compounds with 0-3 isoprene units, whereas CoQ 4 displays only minimal toxicity, evident only at concentrations of around 200 μM 50 , 40 times higher than those employed in this study.
Our findings indicate that CoQ 4 could provide an interesting alternative to CoQ 10 for the treatment of CoQ 10 deficiency in humans. Further studies on animal models are warranted to unravel this issue.
Materials and Methods
Cell culture and chemicals. HEK293, HeLa cells and human fibroblasts were cultured in Dulbecco's Modified Eagle Medium (DMEM, Invitrogen) supplemented with 10% fetal bovine serum (FBS, Invitrogen), 2 mM L-glutamine, 75 U/mL penicillin, 50 µg/mL streptomycin (Invitrogen) at 37 °C in a 5% CO 2 incubator. Fibroblasts of patients with CoQ 10 deficiency were previously described 38, 51 . They had been obtained with the informed consent of the parents of the patients. The study was reviewed by the local ethical committee (Comitato Etico per la Sperimentazione Clinica della Provincia di Padova) -protocol AOPD2019 #0020044). All experiments were performed in accordance with the relevant guidelines and regulations of the University of Padova.
HEK293 COQ4 −/− were generated in our laboratory as described 40 and were cultured in the presence of pyruvate (1 mM) and uridine (50 μg/mL) with 4% FBS, to minimize CoQ 10 content in the medium.
For MRC activity and ATP measurement, cells were cultured for 2 days in DMEM medium containing low glucose (2 mM), to force mitochondrial respiration.
CoQ 10 , MK-4, CoQ 4 and DUB were purchased from Sigma (Milan, Italy). They were dissolved in ethanol and added to the cells as less than 1% of total cell culture volume.
Cell lysates, isolation of mitochondria, western blot, biochemical assays and ATP measurements. Whole-cell lysates were prepared in CHAPS buffer (1% CHAPS, 100 mM KCl, 50 mM HEPES pH 7.5, 1 mM EGTA) supplemented with the complete protease-inhibitor mixture (Sigma). Isolation of mitochondria was performed as detailed elsewhere 52 . Proteins were quantified using the Bradford method (Biorad) and fifty micrograms of proteins were separated by SDS-PAGE. Gels were probed with the following antibodies: COX4 (Thermo Fisher), Lamin A/C (Santa Cruz, USA), Apaf1 (Vinci-Biochem) and secondary HRP-conjugated anti-mouse, anti-rabbit or anti-goat antibodies (Santa Cruz, USA). Visualization of antibody protein complexes was achieved by enhanced chemiluminescence (LiteAblot Turbo, Euroclone) and the ChemiDocTM XRSþSystem (Bio-Rad). The enzymatic activity of RC complexes and citrate synthase (CS) was measured spectrophotometrically as previously described 53 , using a Cary UV 100 spectrophotometer (Varian). Where indicated, RC activities were normalized to CS. Cellular ATP was measured using the ATPlite kit (PerkinElmer), following the manufacturer's instructions. ATP levels were normalized by total protein concentration.
Lipid extraction and measurement of vitamin K2 by HPLC. A mixture of ethanol:hexane (2:5) was added to samples treated with MK-4 and after vortexing for 1 min, they were centrifuged at 2000 g for 5 min at 4 °C. The upper phase was recovered and dried. Lipid extracts were suspended in 150 μl of methanol prior to HPLC injection. Lipid components of the extracts were separated with a Waters Alliance e2695 HPLC system equipped with a vacuum degasser and an electrochemical detector (Antec Decade II). Chromatographic separations were conducted on a C18 4.6 × 150 mm analytical column, 3.5 µm particle size (Varian, Palo Alto, California) maintained at 30 °C. The pump flow rate was 1 mL/min and injection volume was comprised between 2 µL (human cells) and 10 µL (yeast cells). The separation was performed by isocratic elution with a mobile phase constituted by 96% methanol + 4% ethanol and 0.1 M LiClO 4 . The standard solution with vitamin K2 was injected to generate a standard curve that was used to quantify vitamin K2.
Statistical analysis.
Results are expressed as the mean ± SEM values of the indicated number (n) of independent experiments. Statistical significance was determined by unpaired Student's t test between the indicated samples and differences were considered statistically significant for p < 0.05.
Data Availability
All data analyzed during this study are included in this published article and supplemental materials.
